CD274 and non-small cell lung carcinoma: These findings support an emerging body of literature suggesting that ICI use—particularly ICI monotherapy—in ROS1-rearranged NSCLC may elicit an inconsistent and generally poor response [32], implying that PD-L1 expression alone may not be sufficient to predict response to ICI, especially in the presence of a driver mutation [33,34].